Further studies should evaluate multiple predispositions in heart failure prognosis

Author’s response

“…In response to the letter of Aydogan et al [1] concerning our study entitled "The infl uence of acute pulmonary embolism on early and delayed prognosis for patients with chronic heart failure" published in Cardiology Journal [2] we agree that in order to assess major risk factors for mortality in patients with chronic heart failure (CHF) large--scale prospective randomized studies in this group of patients would be of value. It is clear that not only co-morbidities in CHF but also medication used for treatment of co-morbidities and the patients' lifestyles affect complications and the prognosis in this group of patients [3].…”

“…Perhaps CHF patients with high risk of APE recurrence should be treated with anticoagulant therapy much longer and even more intensely during the fi rst months. Similarly to Aydogan et al [1], we also have many questions and doubts concerning the treatment of patients with CHF and APE, and that is why we once again stress that large-scale randomized studies assessing these patients are vital.…”

“…It is clear that not only co-morbidities in CHF but also medication used for treatment of co-morbidities and the patients' lifestyles affect complications and the prognosis in this group of patients [3]. Aydogan et al [1] suggested that the treatment of acute pulmonary embolism (APE) in CHF patients should be longer than the standard 3-month treatment. Authors also stated that CHF is an irreversible and persistent, chronic risk factor for APE and therefore anticoagulants should be prescribed for life long therapy.…”